These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

900 related articles for article (PubMed ID: 24014389)

  • 1. Managing tobacco use: the neglected cardiovascular disease risk factor.
    Rigotti NA; Clair C
    Eur Heart J; 2013 Nov; 34(42):3259-67. PubMed ID: 24014389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking cessation intervention: an evidence-based approach.
    Laniado-Laborín R
    Postgrad Med; 2010 Mar; 122(2):74-82. PubMed ID: 20203458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Methods and results of smoking cessation in cancer smoker's].
    Dautzenberg B
    Bull Cancer; 2012 Nov; 99(11):1007-15. PubMed ID: 23131278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varenicline: a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation.
    Lam S; Patel PN
    Cardiol Rev; 2007; 15(3):154-61. PubMed ID: 17438382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical imperative: assisting patients who smoke to reduce their risk of cardiovascular disease.
    Bullen C; Whittaker R; McRobbie H; Fagerström K
    Prev Cardiol; 2007; 10(2 Suppl 1):5-9. PubMed ID: 17396062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic evaluation based on a randomized placebo-controlled trial of varenicline in smokers with cardiovascular disease: results for Belgium, Spain, Portugal, and Italy.
    Wilson K; Hettle R; Marbaix S; Diaz Cerezo S; Ines M; Santoni L; Annemans L; Prignot J; Lopez de Sa E
    Eur J Prev Cardiol; 2012 Oct; 19(5):1173-83. PubMed ID: 21840967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoking cessation: lessons learned from clinical trial evidence.
    Reid RD; Quinlan B; Riley DL; Pipe AL
    Curr Opin Cardiol; 2007 Jul; 22(4):280-5. PubMed ID: 17556878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategies to help a smoker who is struggling to quit.
    Rigotti NA
    JAMA; 2012 Oct; 308(15):1573-80. PubMed ID: 23073954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current approaches to pharmacotherapy for smoking cessation.
    Hudmon KS; Corelli RL; Prokhorov AV
    Ther Adv Respir Dis; 2010 Feb; 4(1):35-47. PubMed ID: 20056740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoting smoking cessation.
    Larzelere MM; Williams DE
    Am Fam Physician; 2012 Mar; 85(6):591-8. PubMed ID: 22534270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications.
    Jiménez Ruiz CA; Ramos Pinedo A; Cicero Guerrero A; Mayayo Ulibarri M; Cristobal Fernández M; Lopez Gonzalez G
    Nicotine Tob Res; 2012 Sep; 14(9):1035-9. PubMed ID: 22345320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of tobacco smoking and smoking cessation on cardiovascular risk and disease.
    Bullen C
    Expert Rev Cardiovasc Ther; 2008 Jul; 6(6):883-95. PubMed ID: 18570625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a preventive cardiology programme for high CVD risk persistent smokers: the EUROACTION PLUS varenicline trial.
    Jennings C; Kotseva K; De Bacquer D; Hoes A; de Velasco J; Brusaferro S; Mead A; Jones J; Tonstad S; Wood D;
    Eur Heart J; 2014 Jun; 35(21):1411-20. PubMed ID: 24616337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoking cessation in patients with respiratory disease: existing treatments and future directions.
    Rigotti NA
    Lancet Respir Med; 2013 May; 1(3):241-50. PubMed ID: 24429130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking cessation--what works?
    Zwar N
    Aust Fam Physician; 2008; 37(1-2):10-4. PubMed ID: 18239745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoking cessation treatment for COPD smokers: the role of pharmacological interventions.
    Jiménez-Ruiz CA; Fagerström KO
    Monaldi Arch Chest Dis; 2013 Mar; 79(1):27-32. PubMed ID: 23741943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacist "toolbox" for smoking cessation: a review of methods, medicines, and novel means to help patients along the path of smoking reduction to smoking cessation.
    Wynn WP; Stroman RT; Almgren MM; Clark KJ
    J Pharm Pract; 2012 Dec; 25(6):591-9. PubMed ID: 23222855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.